|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:MAP2K1-CUX1 (FusionGDB2 ID:51177) |
Fusion Gene Summary for MAP2K1-CUX1 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: MAP2K1-CUX1 | Fusion gene ID: 51177 | Hgene | Tgene | Gene symbol | MAP2K1 | CUX1 | Gene ID | 5604 | 1523 |
| Gene name | mitogen-activated protein kinase kinase 1 | cut like homeobox 1 | |
| Synonyms | CFC3|MAPKK1|MEK1|MKK1|PRKMK1 | CASP|CDP|CDP/Cut|CDP1|COY1|CUTL1|CUX|Clox|Cux/CDP|GDDI|GOLIM6|Nbla10317|p100|p110|p200|p75 | |
| Cytomap | 15q22.31 | 7q22.1 | |
| Type of gene | protein-coding | protein-coding | |
| Description | dual specificity mitogen-activated protein kinase kinase 1ERK activator kinase 1MAPK/ERK kinase 1MAPKK 1MEK 1protein kinase, mitogen-activated, kinase 1 (MAP kinase kinase 1) | protein CASPHomeobox protein cut-like 1CCAAT displacement proteinCUX1 gene Alternatively Spliced Productcut homologgolgi integral membrane protein 6homeobox protein cux-1putative protein product of Nbla10317 | |
| Modification date | 20200327 | 20200320 | |
| UniProtAcc | Q02750 | P39880 | |
| Ensembl transtripts involved in fusion gene | ENST00000307102, ENST00000566326, | ENST00000292535, ENST00000292538, ENST00000360264, ENST00000393824, ENST00000425244, ENST00000437600, ENST00000546411, ENST00000547394, ENST00000549414, ENST00000550008, ENST00000556210, ENST00000560541, | |
| Fusion gene scores | * DoF score | 8 X 7 X 5=280 | 26 X 23 X 9=5382 |
| # samples | 8 | 29 | |
| ** MAII score | log2(8/280*10)=-1.8073549220576 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(29/5382*10)=-4.21401758562548 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: MAP2K1 [Title/Abstract] AND CUX1 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | MAP2K1(66679765)-CUX1(101870647), # samples:3 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | MAP2K1 | GO:0000187 | activation of MAPK activity | 10644344 |
| Hgene | MAP2K1 | GO:0006468 | protein phosphorylation | 28166211 |
| Hgene | MAP2K1 | GO:0008285 | negative regulation of cell proliferation | 9765203 |
| Hgene | MAP2K1 | GO:0071902 | positive regulation of protein serine/threonine kinase activity | 8388392 |
| Fusion gene breakpoints across MAP2K1 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across CUX1 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | KIRC | TCGA-BP-5192-01A | MAP2K1 | chr15 | 66679765 | - | CUX1 | chr7 | 101870647 | + |
| ChimerDB4 | KIRC | TCGA-BP-5192-01A | MAP2K1 | chr15 | 66679765 | + | CUX1 | chr7 | 101870647 | + |
Top |
Fusion Gene ORF analysis for MAP2K1-CUX1 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 5CDS-intron | ENST00000307102 | ENST00000292535 | MAP2K1 | chr15 | 66679765 | + | CUX1 | chr7 | 101870647 | + |
| 5CDS-intron | ENST00000307102 | ENST00000292538 | MAP2K1 | chr15 | 66679765 | + | CUX1 | chr7 | 101870647 | + |
| 5CDS-intron | ENST00000307102 | ENST00000360264 | MAP2K1 | chr15 | 66679765 | + | CUX1 | chr7 | 101870647 | + |
| 5CDS-intron | ENST00000307102 | ENST00000393824 | MAP2K1 | chr15 | 66679765 | + | CUX1 | chr7 | 101870647 | + |
| 5CDS-intron | ENST00000307102 | ENST00000425244 | MAP2K1 | chr15 | 66679765 | + | CUX1 | chr7 | 101870647 | + |
| 5CDS-intron | ENST00000307102 | ENST00000437600 | MAP2K1 | chr15 | 66679765 | + | CUX1 | chr7 | 101870647 | + |
| 5CDS-intron | ENST00000307102 | ENST00000546411 | MAP2K1 | chr15 | 66679765 | + | CUX1 | chr7 | 101870647 | + |
| 5CDS-intron | ENST00000307102 | ENST00000547394 | MAP2K1 | chr15 | 66679765 | + | CUX1 | chr7 | 101870647 | + |
| 5CDS-intron | ENST00000307102 | ENST00000549414 | MAP2K1 | chr15 | 66679765 | + | CUX1 | chr7 | 101870647 | + |
| 5CDS-intron | ENST00000307102 | ENST00000550008 | MAP2K1 | chr15 | 66679765 | + | CUX1 | chr7 | 101870647 | + |
| 5CDS-intron | ENST00000307102 | ENST00000556210 | MAP2K1 | chr15 | 66679765 | + | CUX1 | chr7 | 101870647 | + |
| 5CDS-intron | ENST00000307102 | ENST00000560541 | MAP2K1 | chr15 | 66679765 | + | CUX1 | chr7 | 101870647 | + |
| intron-intron | ENST00000566326 | ENST00000292535 | MAP2K1 | chr15 | 66679765 | + | CUX1 | chr7 | 101870647 | + |
| intron-intron | ENST00000566326 | ENST00000292538 | MAP2K1 | chr15 | 66679765 | + | CUX1 | chr7 | 101870647 | + |
| intron-intron | ENST00000566326 | ENST00000360264 | MAP2K1 | chr15 | 66679765 | + | CUX1 | chr7 | 101870647 | + |
| intron-intron | ENST00000566326 | ENST00000393824 | MAP2K1 | chr15 | 66679765 | + | CUX1 | chr7 | 101870647 | + |
| intron-intron | ENST00000566326 | ENST00000425244 | MAP2K1 | chr15 | 66679765 | + | CUX1 | chr7 | 101870647 | + |
| intron-intron | ENST00000566326 | ENST00000437600 | MAP2K1 | chr15 | 66679765 | + | CUX1 | chr7 | 101870647 | + |
| intron-intron | ENST00000566326 | ENST00000546411 | MAP2K1 | chr15 | 66679765 | + | CUX1 | chr7 | 101870647 | + |
| intron-intron | ENST00000566326 | ENST00000547394 | MAP2K1 | chr15 | 66679765 | + | CUX1 | chr7 | 101870647 | + |
| intron-intron | ENST00000566326 | ENST00000549414 | MAP2K1 | chr15 | 66679765 | + | CUX1 | chr7 | 101870647 | + |
| intron-intron | ENST00000566326 | ENST00000550008 | MAP2K1 | chr15 | 66679765 | + | CUX1 | chr7 | 101870647 | + |
| intron-intron | ENST00000566326 | ENST00000556210 | MAP2K1 | chr15 | 66679765 | + | CUX1 | chr7 | 101870647 | + |
| intron-intron | ENST00000566326 | ENST00000560541 | MAP2K1 | chr15 | 66679765 | + | CUX1 | chr7 | 101870647 | + |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for MAP2K1-CUX1 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
 |
Top |
Fusion Protein Features for MAP2K1-CUX1 |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:66679765/:101870647) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| MAP2K1 | CUX1 |
| FUNCTION: Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. RAF1 then further activates the dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both MAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERK cascade, and catalyze the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in the extracellular signal-regulated kinases MAPK3/ERK1 and MAPK1/ERK2, leading to their activation and further transduction of the signal within the MAPK/ERK cascade. Activates BRAF in a KSR1 or KSR2-dependent manner; by binding to KSR1 or KSR2 releases the inhibitory intramolecular interaction between KSR1 or KSR2 protein kinase and N-terminal domains which promotes KSR1 or KSR2-BRAF dimerization and BRAF activation (PubMed:29433126). Depending on the cellular context, this pathway mediates diverse biological functions such as cell growth, adhesion, survival and differentiation, predominantly through the regulation of transcription, metabolism and cytoskeletal rearrangements. One target of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotes differentiation and apoptosis. MAP2K1/MEK1 has been shown to export PPARG from the nucleus. The MAPK/ERK cascade is also involved in the regulation of endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC), as well as in the fragmentation of the Golgi apparatus during mitosis. {ECO:0000269|PubMed:14737111, ECO:0000269|PubMed:17101779, ECO:0000269|PubMed:29433126}. | FUNCTION: Transcription factor involved in the control of neuronal differentiation in the brain. Regulates dendrite development and branching, and dendritic spine formation in cortical layers II-III. Also involved in the control of synaptogenesis. In addition, it has probably a broad role in mammalian development as a repressor of developmentally regulated gene expression. May act by preventing binding of positively-activing CCAAT factors to promoters. Component of nf-munr repressor; binds to the matrix attachment regions (MARs) (5' and 3') of the immunoglobulin heavy chain enhancer. Represses T-cell receptor (TCR) beta enhancer function by binding to MARbeta, an ATC-rich DNA sequence located upstream of the TCR beta enhancer. Binds to the TH enhancer; may require the basic helix-loop-helix protein TCF4 as a coactivator. {ECO:0000250|UniProtKB:P53564}.; FUNCTION: [CDP/Cux p110]: Plays a role in cell cycle progression, in particular at the G1/S transition. As cells progress into S phase, a fraction of CUX1 molecules is proteolytically processed into N-terminally truncated proteins of 110 kDa. While CUX1 only transiently binds to DNA and carries the CCAAT-displacement activity, CDP/Cux p110 makes a stable interaction with DNA and stimulates expression of genes such as POLA1. {ECO:0000269|PubMed:15099520}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for MAP2K1-CUX1 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for MAP2K1-CUX1 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for MAP2K1-CUX1 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for MAP2K1-CUX1 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies